The Moving Line: How Diabetes Got Redefined — and Who Profits

A Number That Changed Without You Changing

Imagine your doctor tells you your fasting blood sugar is 108 mg/dL. In 1995, that number meant nothing — you were healthy. Today, it earns you a diagnosis of prediabetes, quarterly monitoring, and probably a conversation about medication.

The number didn't change. The definition of "sick" did.

This is the story of how that happened — who made those decisions, who funded them, and what the science actually supports beneath the official narrative.

By the Numbers

The 46-Year History of a Moving Line

Here is the complete timeline of how America's diabetes thresholds have changed — almost always downward.

1979 — First official threshold: 140 mg/dL

The National Diabetes Data Group sets the first universal fasting glucose threshold. Below 140 mg/dL means you're not diabetic. Simple, stable, universally accepted.

1997 — Diabetes threshold drops to 126 mg/dL

The ADA lowers the diabetes cutoff. The scientific rationale is real: retinal damage from high blood sugar appears at lower glucose levels than 140 mg/dL. The change is widely accepted internationally. It also reclassifies millions of previously "normal" Americans as diabetic overnight.

1997 — Prediabetes created, floor at 110 mg/dL

A new category — "impaired fasting glucose" — is born. If your fasting glucose is 110–125 mg/dL, you're now in a medical gray zone. The WHO adopts this threshold alongside the ADA.

2003 — Prediabetes floor drops again to 100 mg/dL

The ADA lowers the prediabetes floor by 10 points. The World Health Organization refuses to follow. European bodies stay at 110 mg/dL. This single 10-point shift quietly reclassifies tens of millions of healthy adults as pre-sick.

2010 — HbA1c added as a prediabetes trigger

The ADA adds HbA1c of 5.7–6.4% as a second way to diagnose prediabetes. Combined with the lowered glucose floor, more than one in three American adults now qualify as prediabetic — most of whom will never develop diabetes.

The WHO divergence matters. When the world's leading independent health body rejects a threshold change, it is not a minor technical footnote. It is a signal that the decision was contested — and that the science alone did not compel it.

Who Sets the Rules — and Who Funds Them

The ADA is not a government agency. It has no regulatory authority. Yet its annual Standards of Care are adopted wholesale by Medicare, Medicaid, and private insurers as billing and treatment policy. When the ADA moves a number, every doctor's office in America must follow.

Here's the problem: the ADA is substantially funded by the companies that profit when its thresholds go down.

None of this is secret. The ADA publishes its conflict-of-interest disclosures. But disclosure is not the same as independence. A system where the experts defining a disease are paid by the companies treating it is structurally compromised — regardless of any individual's integrity.

The Supply Chain of Sickness

Think of U.S. diabetes medicine as a pipeline. At the top, a nonprofit defines who is sick. At the bottom, pharmaceutical companies sell the treatment. The pipeline only flows in one direction — and it only expands.

A 2019 investigation by Science magazine documented this dynamic in detail: after diabetes drug makers lobbied to make an HbA1c target below 7% a physician performance metric, the diabetes drug market expanded roughly tenfold — from approximately $7 billion in 2000 to over $70 billion by 2020.

What the Science Actually Supports

This is not a story about medicine being wrong. The science behind threshold changes contains real signal — retinopathy does begin at lower glucose levels, and some people with elevated fasting glucose do go on to develop diabetes.

But there are facts the official narrative consistently underemphasizes.

1. Most prediabetics never become diabetics

Many older adults with fasting glucose in the 100–125 mg/dL range will live for decades without progressing to diabetes. The label medicalizes a metabolic state that may never cause harm.

2. The most effective intervention can't be billed

The landmark Diabetes Prevention Program (DPP) trial showed that lifestyle change — diet and exercise — reduces diabetes risk by 58%, outperforming metformin (31% reduction) head-to-head. Yet a physician earns a fraction of the reimbursement from a 45-minute lifestyle counseling session compared with prescribing a GLP-1 drug. The financial architecture of U.S. medicine rewards prescriptions, not prevention.

3. The rest of the world didn't follow

The WHO and most European bodies held their prediabetes threshold at 110 mg/dL and rejected the A1c-based definition. If these were purely neutral scientific conclusions, the global consensus would have aligned. It didn't.

How Institutional Capture Works — Without Anyone Breaking the Rules

There is no smoking gun. No recorded meeting where a pharmaceutical executive hands over a check and says "lower the threshold." The mechanism is more durable than bribery because it is structural:

• Advisory board fees paid to endocrinologists who later vote on guidelines
• Research grants that fund academic careers tied to pharmacological outcomes
• Speaker bureau training that frames prediabetes as a condition requiring ongoing management
• Revolving doors between pharma executive suites and nonprofit boards

Over time, the people defining the disease and the people profiting from it become the same network — and nobody formally did anything wrong.

The result is that when the financial incentive to lower a threshold exists, it gets lowered. When a cure would shrink the market, the incentive points instead toward expanding the patient pool.

Your 100 mg/dL result may be a genuine warning — or it may be a number that was lowered to create a customer. The system is no longer designed to help you tell the difference. That is not an accusation. It is a description of the incentive architecture.

What You Can Actually Do

If you've received a prediabetes diagnosis, you have real options — many of which the system doesn't actively advertise.

1. Ask about your absolute risk, not just your category.

Many people in the 100–110 mg/dL range have low absolute risk of progressing to diabetes, especially if they are older. A threshold-based label tells you where you sit on a number line; it does not tell you what your personal risk trajectory actually is.

2. Ask about the CDC's National Diabetes Prevention Program.

This is a structured lifestyle intervention proven to cut progression risk by 58%. Many insurers now cover it. It is not prominently promoted in most clinical encounters.

3. Ask whether medication is being offered based on your clinical picture — or because your number crosses a guideline threshold.

Those are different conversations. You are entitled to have the second one.

4. Track your own lab data over time.

A single fasting glucose result of 108 mg/dL matters far less than the trend: is it rising? Stable? Falling in response to lifestyle changes? Understanding your own trajectory — not just a single snapshot — is the most clinically meaningful information you can have.

5. Consider a second opinion from a physician with no industry relationships.

They are harder to find — but they exist, and they will give you a different conversation.

The Bigger Picture: Own Your Health Data

The prediabetes story is one instance of a broader pattern: patients receive diagnoses, numbers, and treatment recommendations generated by a system with significant structural financial interests — without the independent analytical layer that would let them evaluate whether that guidance is right for them specifically.

Understanding your own lab results, tracking your own trends over time, and approaching your numbers with context rather than just thresholds is not anti-medicine. It is the foundation of being an informed patient. True health data ownership means having the ability to see your numbers longitudinally — not just receiving a diagnosis at the moment a threshold moves beneath you.

MediSphere helps you do exactly that: organize your health data, understand what your labs mean in context, and build the kind of longitudinal picture that makes every clinical conversation more useful — for you and your doctor.

Sources and fact-check notes: The threshold history (140 → 126 → 110 → 100 mg/dL) is confirmed by ADA Standards of Care (2025, 2026), peer-reviewed historical reviews in The Journal of Clinical Endocrinology & Metabolism (2016) and ScienceDirect (2022), and the ADA's own diagnosis page. The prediabetes population figure (96–98 million) is from the CDC and Precedence Research (2024). The 58% lifestyle risk reduction is from the landmark Diabetes Prevention Program trial, published in NEJM (2002), confirmed by multiple subsequent meta-analyses. Pharmaceutical market figures are from IQVIA and Precedence Research (2024). Conflict-of-interest findings are from peer-reviewed sources as cited inline.